Hims & Hers Drops Wegovy Knockoff Project, Eases Novo Nordisk Competition
Hims & Hers has scrapped plans to develop a Wegovy analog, walking away from its GLP-1 weight-loss injector project within three months of launch plans. Novo Nordisk avoids near-term competition for its Wegovy franchise, preserving its market share in the fast-growing obesity-treatment segment.
1. Hims & Hers Halts Copycat Development
In February 2026, Hims & Hers terminated its GLP-1 weight-loss injector program designed to replicate Novo Nordisk's Wegovy formulation, citing technical and regulatory challenges that made further investment unviable.
2. Novo Nordisk Competitive Outlook
Removal of Hims & Hers as a near-term competitor strengthens Wegovy's incumbency, supporting its premium pricing and enabling Novo Nordisk to maintain market share in the rapidly expanding obesity-treatment segment.
Related News
TSLA
SpaceX $1.25 Trillion IPO Could Lift Musk’s Wealth Above $1 Trillion
TSLA•
VBCJ
Vanguard BondBuilder Corporate ETFs amass $242M, boosting segment to $70B
VBCJ•
APURU
Aperture AC Prices $90 Million IPO of 9 Million Units at $10
APURU•
UXIN
Uxin to Launch 5,000-Vehicle Chongqing Superstore in 2026 Expansion Drive
UXIN•
AVGO
Nvidia Predicts $91B Q3 Sales, Boosts Dividend and $80B Buyback; Broadcom Poised for AI Inference Growth
AVGO•
Sources
F